LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6

LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 34; pp. S1301 - S1302
Main Authors: Garassino, M.C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L.S., Mansy, T., Cortinovis, D.L., Migliorino, M.R., Delmonte, A., García Sanchez, J., Chara Velarde, L.E., Bernabe Caro, R., Paz-Ares, L., Chander, P., Diaz Perez, I., Foroutanpour, K., Faivre-Finn, C.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.10.057